Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;107(8):2500-2506.
doi: 10.1002/jbm.b.34340. Epub 2019 Feb 19.

Osteogenic ability of rat bone marrow concentrate is at least as efficacious as mesenchymal stem cells in vitro

Yusuke Kohno  1 , Tzuhua Lin  1 , Jukka Pajarinen  1 , Monica Romero-Lopez  1 , Masahiro Maruyama  1 , Jhih-Fong Huang  1 , Karthik Nathan  1 , Zhenyu Yao  1 , Stuart B Goodman  1   2
Affiliations

Osteogenic ability of rat bone marrow concentrate is at least as efficacious as mesenchymal stem cells in vitro

Yusuke Kohno et al. J Biomed Mater Res B Appl Biomater. 2019 Nov.

Abstract

Cell therapy using bone marrow concentrate (BMC) or purified and expanded mesenchymal stem cells (MSCs) has been shown to have a promising osteogenic capacity. However, few studies have directly compared their relative osteogenic ability. The aim of this study was to compare the osteogenic ability of BMC isolated by density gradient centrifugation with bone marrow-derived MSCs in vitro using the cells of 3-month-old Sprague-Dawley rats. The isolated cells were seeded onto 24-well plates (1 × 105 cells/well) and cultured in control growth media, osteogenic media with dexamethasone, or media without dexamethasone (which simulated the in vivo tissue environment). Alkaline phosphatase activity at week 2, osteocalcin using quantitative real-time polymerase chain reaction at week 4, and Alizarin red staining at week 4 were evaluated. In the osteogenic media with dexamethasone, BMC showed equivalent (osteocalcin) or even greater (Alizarin red staining) osteogenic ability compared to MSCs, suggesting that cross-talk among various cells in the BMC leads to greater osteogenesis. Furthermore, in the osteogenic media without dexamethasone, BMC showed equivalent (osteocalcin) or a trend for greater (Alizarin red staining) bone formation than MSCs alone. Our results suggest that BMC has at least comparable bone regeneration potential to MSCs. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 107B:2500-2506, 2019.

Keywords: bone marrow concentrate; bone regeneration; cell therapy; mesenchymal stem cell; osteogenesis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Experimental outline of the study. Rat bone marrow cells were collected from the femurs and tibias. BMC and MSCs were isolated and cultured in 3 different kinds of media. Osteogenic ability was evaluated by ALP activity assay, osteocalcin (qRT-PCR), and Alizarin red staining.
Fig. 2
Fig. 2
The immunophenotype of the isolated rat MSCs was characterized by flow cytometry (CD90+/CD146+/CD44+/CD45−/CD31−/CD11b−).
Fig. 3
Fig. 3
Tri-lineage differentiation was confirmed by Alizarin red staining (osteogenesis) (A, B), Oil red O staining (adipogenesis) (C, D), and toluidine blue staining (chondrogenesis) (E, F), respectively.
Fig. 4
Fig. 4
ALP activity assay. All the groups of MSCs showed significantly higher ALP activity than the corresponding groups of BMC. *p <0.05, **p <0.01, ***p <0.005
Fig. 5
Fig. 5
Osteocalcin (qRT-PCR). The osteogenic media with DEX group of MSCs showed significantly higher osteocalcin level than the other groups of MSCs, and also showed the comparable osteocalcin level to that of BMC. **p <0.01, ***p <0.005
Fig. 6
Fig. 6
Alizarin red staining. The osteogenic media with DEX group of BMC showed significantly stronger staining than the other groups of BMC, and also showed significantly stronger staining than that of MSCs. The osteogenic media without DEX group of BMC showed a trend of stronger staining than that of MSCs. **p <0.01, ***p <0.005
See this image and copyright information in PMC

References

    1. Caplan AI, Mason C, Reeve B. The 3Rs of cell therapy. Stem Cells Transl Med 2017;6:17–21. - PMC - PubMed
    1. Yorukoglu AC, Kiter AE, Akkaya S, Satiroglu-Tufan NL, Tufan AC. A concise review on the use of mesenchymal stem cells in cell sheet-based tissue engineering with special emphasis on bone tissue regeneration. Stem Cells Int 2017;2017:2374161. - PMC - PubMed
    1. Smith JO, Aarvold A, Tayton ER, Dunlop DG, Oreffo RO. Skeletal tissue regeneration: current approaches, challenges, and novel reconstructive strategies for an aging population. Tissue Eng Part B Rev 2011;17:307–320. - PubMed
    1. Marler JJ, Upton J, Langer R, Vacanti JP. Transplantation of cells in matrices for tissue regeneration. Adv Drug Deliv Rev 1998;33:165–182. - PubMed
    1. Goodman SB. Cell-based therapies for regenerating bone. Minerva Ortop Traumatol 2013;64:107–113. - PMC - PubMed

Publication types

LinkOut - more resources